These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 24357432)

  • 1. Cost-effectiveness of prenatal screening strategies for congenital heart disease.
    Pinto NM; Nelson R; Puchalski M; Metz TD; Smith KJ
    Ultrasound Obstet Gynecol; 2014 Jul; 44(1):50-7. PubMed ID: 24357432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of fetal cardiac anomalies: cost-effectiveness of increased number of cardiac views.
    Bak GS; Shaffer BL; Madriago E; Allen A; Kelly B; Caughey AB; Pereira L
    Ultrasound Obstet Gynecol; 2020 Jun; 55(6):758-767. PubMed ID: 31945242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of prenatal screening methods for congenital heart defects in pregnancies conceived by in-vitro fertilization.
    Chung EH; Lim SL; Havrilesky LJ; Steiner AZ; Dotters-Katz SK
    Ultrasound Obstet Gynecol; 2021 Jun; 57(6):979-986. PubMed ID: 32304621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of maternal obesity on fetal cardiac screening: which follow-up strategy is cost-effective?
    Bak GS; Shaffer BL; Madriago E; Allen A; Kelly B; Caughey AB; Pereira L
    Ultrasound Obstet Gynecol; 2020 Nov; 56(5):705-716. PubMed ID: 31614030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness, the economic considerations of prenatal screening strategies for trisomy 21 in the Czech Republic.
    Dhaifalah I; Májek O
    Ceska Gynekol; 2012 Feb; 77(1):39-51. PubMed ID: 22536640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The role of fetal nuchal translucency (NT) and ductus venosus blood flow (DV) in the detection of congenital heart defects].
    Baś-Budecka E; Perenc M; Sieroszewski P
    Ginekol Pol; 2010 Apr; 81(4):272-6. PubMed ID: 20476599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of prenatal diagnosis on congenital heart defects.
    DeVore GR
    Ann N Y Acad Sci; 1998 Jun; 847():46-52. PubMed ID: 9668697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reducing the cost of detection of congenital heart disease in fetuses of women with pregestational diabetes mellitus.
    Bernard LS; Ramos GA; Fines V; Hull AD
    Ultrasound Obstet Gynecol; 2009 Jun; 33(6):676-82. PubMed ID: 19479684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should all pregnant diabetic women undergo a fetal echocardiography? A cost-effectiveness analysis comparing four screening strategies.
    Odibo AO; Coassolo KM; Stamilio DM; Ural SH; Macones GA
    Prenat Diagn; 2006 Jan; 26(1):39-44. PubMed ID: 16378332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-trimester fetal cardiac examination using spatiotemporal image correlation, tomographic ultrasound and color Doppler imaging for the diagnosis of complex congenital heart disease in high-risk patients.
    Turan S; Turan OM; Desai A; Harman CR; Baschat AA
    Ultrasound Obstet Gynecol; 2014 Nov; 44(5):562-7. PubMed ID: 24585667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prenatal screening for fetal aneuploidy in singleton pregnancies.
    Chitayat D; Langlois S; Douglas Wilson R; ;
    J Obstet Gynaecol Can; 2011 Jul; 33(7):736-750. PubMed ID: 21749752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell-free fetal DNA screening in the USA: a cost analysis of screening strategies.
    Evans MI; Sonek JD; Hallahan TW; Krantz DA
    Ultrasound Obstet Gynecol; 2015 Jan; 45(1):74-83. PubMed ID: 25315699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fetal echocardiography at the time of the nuchal translucency scan.
    Lombardi CM; Bellotti M; Fesslova V; Cappellini A
    Ultrasound Obstet Gynecol; 2007 Mar; 29(3):249-57. PubMed ID: 17318942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Universal Fetal Echocardiography for Pregestational Diabetes Mellitus: A Cost-Effectiveness Analysis.
    Savitsky LM; Hamilton C; Sterrett M; Olerich K; Ma K; Albright CM
    Obstet Gynecol; 2024 Nov; 144(5):715-724. PubMed ID: 38422504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Ultrasound soft markers and fetal cardiac structural assessment at 11-14 weeks].
    Yang Y; Zhang Y
    Zhonghua Fu Chan Ke Za Zhi; 2014 Mar; 49(3):188-92. PubMed ID: 24820303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prenatal detection of congenital heart disease in a low risk population undergoing first and second trimester screening.
    Jørgensen DE; Vejlstrup N; Jørgensen C; Maroun LL; Steensberg J; Hessellund A; Jørgensen FS; Larsen T; Shalmi AC; Skibsted L; Zingenberg H; Ekelund C; Tabor A
    Prenat Diagn; 2015 Apr; 35(4):325-30. PubMed ID: 25352400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using second trimester ultrasound and maternal serum biomarker data to help detect congenital heart defects in pregnancies with positive triple-marker screening results.
    Jelliffe-Pawlowski LL; Walton-Haynes L; Currier RJ
    Am J Med Genet A; 2008 Oct; 146A(19):2455-67. PubMed ID: 18785270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of congenital heart defects throughout pregnancy; impact of first trimester ultrasound screening for cardiac abnormalities.
    Eleftheriades M; Tsapakis E; Sotiriadis A; Manolakos E; Hassiakos D; Botsis D
    J Matern Fetal Neonatal Med; 2012 Dec; 25(12):2546-50. PubMed ID: 22712625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nuchal translucency measurement and congenital heart defects: modest association in low-risk pregnancies.
    Müller MA; Clur SA; Timmerman E; Bilardo CM
    Prenat Diagn; 2007 Feb; 27(2):164-9. PubMed ID: 17238215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cost effectiveness of prenatal ultrasound screening for trisomy 21.
    Harris AH
    Int J Technol Assess Health Care; 2004; 20(4):464-8. PubMed ID: 15609796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.